STM-2457 (STM2457; STM 2457) is a novel, first-in-class, orally bioactive and selective catalytic inhibitor of METTL3 (IC50 =16.9 nM) with potential antineoplastic activity. It has the potential to be used for the treatment of acute myeloid leukaemia (AML). The m6A methyltransferase METTL3 has been linked to the initiation and maintenance of acute myeloid leukaemia (AML), but the potential of therapeutic applications targeting this enzyme remains unknown.

纯度：≥98%

CAS：2499663-01-1